Table 1 Patient Demographic Characteristics.

From: Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis

 

Numbers

Patients (n)

73

Median age (range), years

48 (24–76)

Tumor histology

69 IDC, 1 ILC, 2 MpC, 1 MC

Clinical T stage*

 T1

0

 T2

44 (60.3%)

 T3

24 (32.9%)

 T4

5 (7.8%)

Clinical N stage*

 N0

20 (27.4%)

 N1

30 (41.1%)

 N2

17 (23.3%)

 N3

6 (8.2%)

Stage*

 IIa

13 (17.8%)

 IIb

25 (34.2%)

 IIIa

24 (32.9%)

 IIIb

4 (5.5%)

 IIIc

6 (8.2%)

Clinical subtype†

 HR-positive/HER2-negative

25 (36.8%)

 HER2-positive

18 (26.5%)

 TNBC

25 (36.8%)

Surgery

 BCS

36 (49.3%)

 Mastectomy

37 (50.7%)

Response to NAC

 pCRs

17 (23.3%)

 Non-pCRs

56 (76.7%)

Recurrence†

4 (5.5%)

DFS (range), months‡

25 (16–57)

  1. *Staging was defined according to the American Joint Committee on Cancer system 7th edition; †Five cases with moderate HER2 staining were excluded from subgroup analysis due to lack of HER2 FISH result; ‡Recurrence and DFS was about 66 cases included in survival analysis. Notes: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MpC, metaplastic carcinoma; MC, mucinous carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; BCS, breast conserving surgery; NAC, neoadjuvant chemotherapy; pCR, pathological complete response; DFS, disease-free-survival.
Back to article page